In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Science

Edwards’ CSO: Acquisitions Are Not The Only Way To Drive A Medtech Growth Strategy

In following his passion to make an impact in clinical outcomes, Todd Brinton has been back-and-forth across the medtech map since leaving university. Now in a senior role at Edwards Lifesciences, he is not letting up on his quest to continuously innovate and make a difference in clinical care.

Leadership Medical Device

Finding A Way To Bring Graphene To Diagnostics

UK-based Paragraf is working on a range of diagnostic sensors built using graphene, allowing for faster, more sensitive testing products.

Financing Innovation

Prevention Better Than Cure? AC Immune's Parkinson’s Vaccine Approach

With a broad pipeline focused on neurodegenerative disease, AC Immune is about to begin a Phase II program investigating an alpha-synuclein-targeted peptide vaccine with a diagnostic to stratify patients.

New Science Innovation

Science Matters: Harnessing The Inherent Power Of MAIT Cells

Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.

New Science Innovation

Funding The Future: Accelerating The Long Walk To Innovation

In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.

New Science StartUps and SMEs

Micro-Dosing Gene Therapy: A Recipe For Success?

Utilizing the genetic overlap between frontotemporal dementia and amyotrophic lateral sclerosis, AviadoBio is seeking to develop gene therapies which can stop both these devastating diseases in their tracks using novel delivery techniques.

New Science Gene Therapy

Snapshot: June Highlights

A selection of articles you might have missed from June 2022, including a deep dive into venture finance, an in depth discussion about Russia's upcoming drug supply woes, and the latest Rising Leaders interviews.

New Science Market Intelligence

What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About

Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.

New Science Leadership
UsernamePublicRestriction

Register